Innovation in Cardiology--and Beyond.

For years, cardiovascular devices were the main focus of venture investors and the start-ups they backed. But in recent years, innovation in cardiovascular has grown more challenging, perhaps in part because of the way drug-eluting stents have reshaped the market, while other clinical spaces have opened up as promising technological and commercials opportunities. In this discussion, a distinguished group of physicians, product developers, and entrepreneurs look at where innovation is going and the challenges small companies face.

Few would contest that the past quarter-century has seen an explosion of medical device technology that has brought incalculable benefit to patients and, despite some down times, abundant riches to inventors and the investors who’ve backed them. By its very nature, device innovation is incremental: most often serving as tools in the hands of skilled physicians and surgeons, innovative devices build on the clinical success of existing technology in enhancements large and small, though usually small. It is an innovation model that has served the device industry well.

And yet, despite the clinical advances and financial successes that have flowed from new technology, fostering meaningful innovation seems only...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

How Ethris Cracked mRNA’s “Do Not Shake” Problem To Unlock Respiratory Therapeutics

 
• By 

A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo